• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

药品数据保护制度对药品可及性负效应研究——基于美国拉莫三嗪案例的实证分析

丁锦希, 刘阳阳, 颜建周

丁锦希, 刘阳阳, 颜建周. 药品数据保护制度对药品可及性负效应研究——基于美国拉莫三嗪案例的实证分析[J]. 中国药科大学学报, 2015, 46(4): 493-498. DOI: 10.11665/j.issn.1000-5048.20150418
引用本文: 丁锦希, 刘阳阳, 颜建周. 药品数据保护制度对药品可及性负效应研究——基于美国拉莫三嗪案例的实证分析[J]. 中国药科大学学报, 2015, 46(4): 493-498. DOI: 10.11665/j.issn.1000-5048.20150418
shu
DING Jinxi, LIU Yangyang, YAN Jianzhou. Negative effects of drug data protection system on drug availability — an empirical analysis of America lamotrigine case[J]. Journal of China Pharmaceutical University, 2015, 46(4): 493-498. DOI: 10.11665/j.issn.1000-5048.20150418
Citation: DING Jinxi, LIU Yangyang, YAN Jianzhou. Negative effects of drug data protection system on drug availability — an empirical analysis of America lamotrigine case[J]. Journal of China Pharmaceutical University, 2015, 46(4): 493-498. DOI: 10.11665/j.issn.1000-5048.20150418
shu

药品数据保护制度对药品可及性负效应研究——基于美国拉莫三嗪案例的实证分析

  • 中国药科大学国际医药商学院

基金项目: 国家社会科学基金资助项目(No.13BFX120)

Negative effects of drug data protection system on drug availability — an empirical analysis of America lamotrigine case

摘要

    摘要
  • 摘要: 通过美国上市的拉莫三嗪案例，探究药品数据保护制度与药品可及性之间的关系。研究表明，药品数据保护制度延迟仿制药上市周期，无法及时有效地平抑创新药垄断高价，从而降低了用药可及性。建议我国合理设计药品数据保护制度的应用范围，并设置首仿药制度和配套措施，控制药品数据保护制度负效应，保障公众健康福利。
    Abstract: This paper explores the relevance between data protection system and drug availability through the American lamotrigine(lamictal® )case. Results indicated that drug data protection system delays the marketing of genetics, hinders the pricing regulation of innovative drugs timely and effectively, and affects drug availability severely. With reference to America, it is urgent to design the scope of data protection system reasonably, and set the first generic drug regime and other supporting measures so as to reduce the negative effects of drug data protection system and improve the health benefits of the public.
    • HTML全文
    • 参考文献(20)
  • [1] Diao TX,Wu SH.The analysis of status and effect of the protection of drug test data[J].Bull Acad Mil Med Sci(军事医学科学院院刊),2007,31(2):160-162.
    [2] Wu SW,Han S,Cheng J,et al.Impact of medical data protection on drug expenditure and accessibility in China[J].Chin Pharm J(中国新药杂志),2012,21(20):2353-2355.
    [3] WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy-2000-2003[EB/OL].[2014-12-26] http://apps.who.int/medicinedocs/en/d/Jwhozip16e/1.html.
    [4] Gong SW.Study of management strategies of improving access to orphan drugs in China(促进我国罕见病患者药品可及性的管理策略研究)[D].Hubei:Huazhong University of Science and Technology,2008.
    [5] Jiang S.Policy to improve drug accessibility-compulsory license[J].Economic Tribune(经济论坛),2004,12:122-123.
    [6] Li HT.Analysis on the accessibility of drugs in China[J].Chin Health Serve Manage(中国卫生事业管理),2009,9:612-614.
    [7] Liu B,Wu RX,Ye L.Barrier of availability and accessibility to essential drugs[J].Chin Pharm(中国药房),2007,18(14):1041-1043.
    [8] Ding JX,Li XT,Zhao Y.The unify operation pattern of drug reimbursement list under the policy of new medical reform-based on the empirical analysis of the drug reimbursement list of new cooperation medical system[J].Chin Pharm Aff(中国药事),2011,25(10):962-968.
    [9] Li P.Study on strategies of improving access to essential medicines in rural of China(改善农村地区基本药物可获得性策略研究)[D].Hubei:Huazhong University of Science and Technology,2009.
    [10] Gong SW,Xu Y,Zhang L.study on evaluator indication system of drug accessibility[J].Chin Health Econ(中国卫生经济),2011,30(5):72-74.
    [11] Ding JX, Zhao M. The comparative study on supervision and incentive policies of sino-US during the innovative drug R&D[J].Chin J New Drugs(中国新药杂志),2009,18(5):387-396.
    [12] Yu XQ.Evolution of American generics[J].Chin J Pres Drug(中国处方药杂志),2008,78:47-50.
    [13] FDA Approved Drug Products.[EB/OL].[2014-02-13] http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
    [14] FDA Approved Drug Products.[EB/OL].[2014-02-13] http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=LAMOTRIGINE.
    [15] Yang L,Li Y.A study on data exclusivity protection for pharmaceutical products in the USA[J].Chin Pharm(中国药房),2007,18(10):730-734.
    [16] Zhang RW,Hu SL.A comparative study of international price for pharmaceuticals medicine price[J].Chin Health Econ(中国卫生经济),2001,20(2):26-28.
    [17] Lamictal Prices,Coupons and Patient Assistance Programs.[EB/OL].[2014-03-10] http://www.drugs.com/price-guide/lamictal.
    [18] US Bureau of Labor Statistics.[EB/OL].[2014-03-11] http://www.bls.gov.
    [19] Xu K.Distribution of health payment and catastrophic expenditure methodology.Geneva:department of health system financing[R].World health organization,2005.
    [20] Jesse C.Vivia.Generic-Substitution Laws[J].US Pharm,2008,33(6):30-34.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1021
  • HTML全文浏览量:  3
  • PDF下载量:  2084
  • 被引次数: 0
出版历程
  • 刊出日期:  2015-08-24

目录

摘要
HTML全文
    参考文献(20)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：323958

    x 关闭 永久关闭